Laura D Almquist1, Creighton E Likes1, Benjamin Stone2, Kaitlin R Brown3, Ricardo Savaris4, David A Forstein1, Paul B Miller1, Bruce A Lessey5. 1. Department of Obstetrics and Gynecology, Greenville Health System, Greenville, South Carolina. 2. Department of Biology, Bowdoin College, Brunswick, Maine. 3. Obstetrics and Gynecology, University of South Carolina SOM-Greenville, Greenville, South Carolina. 4. Departamento de Ginecologia e Obstetrícia, Universidade Federal do Rio Grande do Sul, Rio Grande do Sul, Brazil. 5. Department of Obstetrics and Gynecology, Greenville Health System, Greenville, South Carolina. Electronic address: blessey@ghs.org.
Abstract
OBJECTIVE: To evaluate endometrial BCL6 expression as a prognostic biomarker for IVF outcome in women with unexplained infertility (UI) before ET. DESIGN: Prospective cohort study. SETTING: University-associated infertility clinic. PATIENT(S): Women with UI for >1 year. INTERVENTION(S): We studied women with UI who underwent testing for endometrial BCL6, in an LH-timed midluteal phase biopsy and completed an IVF cycle and ET. MAIN OUTCOME MEASURE(S): Clinical pregnancy rate (PR) and live birth rate per transfer was compared for women positive or negative for BCL6 expression. An abnormal BCL6 result was defined by an histologic score (>1.4). RESULT(S): Women with normal and abnormal BCL6 and those who conceived or not had similar characteristics. Women with low levels of BCL6 expression had a significantly higher clinical PR (11/17; 64.7%; 95% confidence interval [CI] 41.3-82.6) compared with women with abnormal (high) BCL6 expression (9/52; 17.3%; 95% CI 9.3-30.8). These results yield a relative risk of 0.267 (95% CI 0.13-0.53; P=.0004) for those with normal BCL6 expression, an absolute benefit of 47.4% (95% CI 22.5-72.0). Live birth rate was also significantly higher in women with low BCL6 expression (10/17; 58.8%; 95% CI 36.0-78.4) compared with women with abnormal BCL6 expression (6/52; 11.5%; 95% CI 5.4-23.0). The relative risk was 0.19 (95% CI 0.08-0.45; P=.0002), yielding an absolute benefit of 47.3% (95% CI 21.8-67.8). CONCLUSION(S): Aberrant BCL6 expression (histologic score, >1.4) was strongly associated with poor reproductive outcomes in IVF cycles in women with UI.
OBJECTIVE: To evaluate endometrial BCL6 expression as a prognostic biomarker for IVF outcome in women with unexplained infertility (UI) before ET. DESIGN: Prospective cohort study. SETTING: University-associated infertility clinic. PATIENT(S): Women with UI for >1 year. INTERVENTION(S): We studied women with UI who underwent testing for endometrial BCL6, in an LH-timed midluteal phase biopsy and completed an IVF cycle and ET. MAIN OUTCOME MEASURE(S): Clinical pregnancy rate (PR) and live birth rate per transfer was compared for women positive or negative for BCL6 expression. An abnormal BCL6 result was defined by an histologic score (>1.4). RESULT(S): Women with normal and abnormal BCL6 and those who conceived or not had similar characteristics. Women with low levels of BCL6 expression had a significantly higher clinical PR (11/17; 64.7%; 95% confidence interval [CI] 41.3-82.6) compared with women with abnormal (high) BCL6 expression (9/52; 17.3%; 95% CI 9.3-30.8). These results yield a relative risk of 0.267 (95% CI 0.13-0.53; P=.0004) for those with normal BCL6 expression, an absolute benefit of 47.4% (95% CI 22.5-72.0). Live birth rate was also significantly higher in women with low BCL6 expression (10/17; 58.8%; 95% CI 36.0-78.4) compared with women with abnormal BCL6 expression (6/52; 11.5%; 95% CI 5.4-23.0). The relative risk was 0.19 (95% CI 0.08-0.45; P=.0002), yielding an absolute benefit of 47.3% (95% CI 21.8-67.8). CONCLUSION(S): Aberrant BCL6 expression (histologic score, >1.4) was strongly associated with poor reproductive outcomes in IVF cycles in women with UI.
Authors: Emily Evans-Hoeker; Bruce A Lessey; Jae Wook Jeong; Ricardo F Savaris; Wilder A Palomino; Lingwen Yuan; David P Schammel; Steven L Young Journal: Reprod Sci Date: 2016-05-24 Impact factor: 3.060
Authors: Manal A Tawfeek; Manal A Eid; Azza M Hasan; Manal Mostafa; Hesham A El-Serogy Journal: BMC Womens Health Date: 2012-04-20 Impact factor: 2.809
Authors: Creighton E Likes; Leah J Cooper; Jessica Efird; David A Forstein; Paul B Miller; Ricardo Savaris; Bruce A Lessey Journal: J Assist Reprod Genet Date: 2019-01-04 Impact factor: 3.412
Authors: Mengni Shen; Elizabeth O'Donnell; Gabriela Leon; Ana Kisovar; Pedro Melo; Krina Zondervan; Ingrid Granne; Jennifer Southcombe Journal: Hum Reprod Open Date: 2021-12-25